Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.6615 -0.0185 (-2.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 873,310
Open 0.6996
Bid (Size) 0.6800 (3)
Ask (Size) 0.7050 (30)
Prev. Close 0.6800
Today's Range 0.6600 - 0.6999
52wk Range 0.4300 - 3.880
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
Via TheNewswire.com
GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-73.3%
-73.3%
1 Month
-6.4%
-6.4%
3 Month
-29.9%
-29.9%
6 Month
-51.0%
-51.0%
1 Year
-75.4%
-75.4%

More News

Read More
GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
Via NewMediaWire
GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
Via TheNewswire.com
GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference
Via NewMediaWire
GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences
Via TheNewswire.com
GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Via TheNewswire.com
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
Via TheNewswire.com
Topics Intellectual Property
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
Via TheNewswire.com
GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference
Via TheNewswire.com
GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences
Via NewMediaWire
GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Via NewMediaWire
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
Via NewMediaWire
Topics Intellectual Property
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
Via NewMediaWire
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
Via TheNewswire.com
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
Via TheNewswire.com
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
Via TheNewswire.com
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
Via NewMediaWire
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
Via NewMediaWire
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
Via TheNewswire.com
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
Via NewMediaWire
Topics Death
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
Via TheNewswire.com
Topics Death
GeoVax Labs Revenue Doubles in Q2
Via The Motley Fool
Topics Intellectual Property
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
Via NewMediaWire
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
Via NewMediaWire

Frequently Asked Questions

Is GeoVax Labs, Inc. - Common Stock publicly traded?
Yes, GeoVax Labs, Inc. - Common Stock is publicly traded.
What exchange does GeoVax Labs, Inc. - Common Stock trade on?
GeoVax Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeoVax Labs, Inc. - Common Stock?
The ticker symbol for GeoVax Labs, Inc. - Common Stock is GOVX on the Nasdaq Stock Market
What is the current price of GeoVax Labs, Inc. - Common Stock?
The current price of GeoVax Labs, Inc. - Common Stock is 0.6615
When was GeoVax Labs, Inc. - Common Stock last traded?
The last trade of GeoVax Labs, Inc. - Common Stock was at 09/18/25 04:00 PM ET
What is the market capitalization of GeoVax Labs, Inc. - Common Stock?
The market capitalization of GeoVax Labs, Inc. - Common Stock is 1.44M
How many shares of GeoVax Labs, Inc. - Common Stock are outstanding?
GeoVax Labs, Inc. - Common Stock has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.